CAMP4 Therapeutics (NASDAQ:CAMP) CFO Kelly Gold Acquires 10,000 Shares

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CFO Kelly Gold purchased 10,000 shares of the stock in a transaction dated Monday, August 31st. The stock was acquired at an average cost of $3.96 per share, for a total transaction of $39,600.00. Following the transaction, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Kelly Gold also recently made the following trade(s):

• On Monday, August 3rd, Kelly Gold purchased 6,551 shares of CAMP4 Therapeutics stock. The shares were acquired at an average price of $1.65 per share, for a total transaction of $10,809.15.

CAMP4 Therapeutics Trading Up 0.3%

CAMP opened at $3.80 on Thursday. CAMP4 Therapeutics Corporation has a 12 month low of $1.41 and a 12 month high of $7.75. The company has a market cap of $238.45 million, a PE ratio of -1.64 and a beta of 0.27. The company has a 50 day moving average of $4.11 and a 200 day moving average of $4.34.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. Research analysts forecast that CAMP4 Therapeutics Corporation will post -0.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CAMP has been the topic of a number of analyst reports. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a research note on Friday, August 14th. Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Finally, Piper Sandler restated an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.56.

Institutional Investors Weigh In On CAMP4 Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CAMP. Jupiter Topco LLC bought a new stake in CAMP4 Therapeutics during the second quarter valued at $27,581,000. 5AM Venture Management LLC bought a new position in CAMP4 Therapeutics in the 2nd quarter worth about $25,647,928. Vivo Capital LLC bought a new position in CAMP4 Therapeutics in the 3rd quarter worth about $11,765,000. Balyasny Asset Management L.P. purchased a new stake in shares of CAMP4 Therapeutics in the 4th quarter valued at about $14,938,000. Finally, Trails Edge Capital Partners LP purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $8,446,935.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.